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Abstract
Over the past decade, the number of reported human immunodeficiency virus type-1 (HIV-1)/Leishmania co-infections has
risen dramatically, particularly in regions where both diseases are endemic. Although it is known that HIV-1 infection leads
to an increase in susceptibility to Leishmania infection and leishmaniasis relapse, little remains known on how HIV-1
contributes to Leishmania parasitaemia. Both pathogens infect human macrophages, and the intracellular growth of
Leishmania is increased by HIV-1 in co-infected cultures. We now report that uninfected bystander cells, not macrophages
productively infected with HIV-1, account for enhanced phagocytosis and higher multiplication of Leishmania parasites. This
effect can be driven by HIV-1 Tat protein and transforming growth factor-beta (TGF-b). Furthermore, we show for the first
time that HIV-1 infection increases surface expression of phosphatidylserine receptor CD91/LRP-1 on human macrophages,
thereby leading to a Leishmania uptake by uninfected bystander cells in HIV-1-infected macrophage populations. The more
important internalization of parasites is due to interactions between the scavenger receptor CD91/LRP-1 and
phosphatidylserine residues exposed at the surface of Leishmania. We determined also that enhanced CD91/LRP-1 surface
expression occurs rapidly following HIV-1 infection, and is triggered by the activation of extracellular TGF-b. Thus, these
results establish an intricate link between HIV-1 infection, Tat, surface CD91/LRP-1, TGF-b, and enhanced Leishmania
phosphatidylserine-mediated phagocytosis.
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Introduction
The continuing expansion of the AIDS pandemic has resulted
in the establishment of new opportunistic diseases which take
advantage of the immunocompromised state prevailing in
individuals infected with human immunodeficiency virus type-1
(HIV-1) [1–3]. Of these newly recognized opportunistic patho-
gens, Leishmania has risen to considerable importance over the past
decade, in large part due to the increased urbanization of (and
HIV-1 access to) rural regions in developing countries, and the co-
transmission of this protozoan parasite and HIV-1 through the use
of contaminated seringes by intravenous drug users [1,2]. If HIV-1
has ultimately altered the medical, biological and pharmacological
aspects of leishmaniasis, Leishmania exacerbates HIV-1 infection,
complicating treatment and diminishing life expectancy of AIDS
patients [1,2].
Leishmania causes several tropical diseases in humans, of which
one, visceral leishmaniasis (VL), is potentially fatal. Indeed, over
300,000 new cases of VL are reported annually worldwide, and it
is considered to be a major health concern in several developing
countries [1]. VL is caused by either one of the closely related
species, i.e. Leishmania donovani (L. donovani), L. infantum or L. chagasi,
and is characterized by hepato-splenomegaly and a massive
infection of the reticoendothelial system. The biphasic life cycle of
the parasite alternates between motile promastigotes, which are
transmitted by the bite of infected sandflies, and the non-motile
amastigotes, the major form of the parasite found in humans,
which replicate in intracellular phagosomes of infected monocytes
and macrophages.
HIV-1 also infects cells of the monocyte lineage (i.e.
macrophages and dendritic cells), which act as potential reservoirs
for viral replication [4,5]. It has been shown that both Leishmania
and HIV-1 greatly impact on macrophage functions, and
particularly influence immune response and cytokine production.
For example, HIV-1 infection of monocyte-derived macrophages
(MDMs) in vitro generally inhibits phagocytosis [6–9] and elicits a
cytokine response leading to secretion of tumor necrosis factor-
alpha (TNF-a), interleukin-1 (IL-1), IL-6 and IL-8, among others
[10]. The presence of these cytokines greatly impacts on Leishmania
infection and multiplication in the case of co-infections [1]. In this
regard, it has been reported that HIV-1 infection augments L.
infantum multiplication in MDMs [11], and that, conversely,
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production of TNF-a and IL-1a [12,13]. Interestingly, HIV-1
augments intake and replication of Leishmania in MDMs [11],
which is unusual given that, as mentioned above, HIV-1 infection
has been shown to inhibit phagocytosis [6–8]. Finally, Barreto de
Souza and colleagues found that the HIV-1 transactivating protein
Tat, through the expression of cyclooxygenase-2, prostaglandin E2
synthesis and the effect of transforming growth factor-beta (TGF-
b), mediates increased Leishmania replication in co-infected
macrophage populations [14]. More recently similar observations
were found with the non-pathogenic trypanosomatid Blastocrithidia
culicis [15].
The precise mechanism(s) by which HIV-1 augments engulf-
ment and replication of Leishmania parasites in macrophages, still
remains poorly understood. Although we herein confirmed the
previously reported enhancing effect of Tat and TGF-b on
parasite internalization by MDMs [14], we also found that
uninfected bystander macrophages respond to soluble factors
secreted by their HIV-1-infected cellular counterparts, and that
the former cell population greatly accounts for the reported
enhancing effect on Leishmania internalization [14]. Furthermore,
we demonstrate that uninfected bystander macrophages, through
HIV-1-mediated induction of greater surface expression of CD91/
LRP-1 (the low density lipoprotein receptor-related protein 1)
more actively bind phosphatidylserines located at the surface of
the parasite, eventually leading to a superior Leishmania entry and
replication in the uninfected bystander macrophage subpopula-
tion.
Materials and Methods
Establishment and culture of MDMs
Human peripheral blood mononuclear cells (PBMCs) were
obtained from healthy blood donors, in accordance with the
guidelines of the Bioethics Committee of the CHUL Research
Center, by density-gradient centrifugation on Ficoll-Hypaque
(Wisent, St-Bruno, QC). All blood donors were informed and
agreed to a written consent prior to donating blood. Monocytes
were purified by adherence in RPMI-1640 medium (Wisent)
supplemented with 5% decomplemented autologous human
serum, and allowed to differentiate into MDMs for 6–7 days in
RPMI-1640 medium supplemented with 5% autologous human
serum and human recombinant macrophage colony-stimulating
factor (100 ng/ml, Genscript, Piscataway, NJ). MDMs were
harvested by addition of Accutase (eBioscience, San Diego, CA)
followed by gentle scraping, and transferred to 6-well or 24-well
plates containing glass coverslides (12 mm round, thickness #1,
Fisher Scientific, Nepean, ON), at 24 hours prior to HIV-1
infection or cytokine treatments. Following transfer to 6- or 24-
well plates, MDMs were cultured in RPMI-1640 supplemented
with 5% autologous human serum.
HIV-1 production and MDM infection
The infectious molecular clone NL4-3-Bal-IRES-HSA was
recently described [16]. Briefly, besides encoding all HIV-1
proteins and producing R5 (Bal)-tropic HIV-1 virions, this NL4-
3-based vector additionally codes for the cell surface murine heat-
stable antigen (HSA)/CD24, enabling for efficient early identifi-
cation of productively infected cells. Fully competent NL4-3-Bal-
IRES-HSA viruses were produced by transient expression in
calcium-phosphate transfected 293T cells, and stocks quantitated
using an in-house ELISA assay specific for major capsid protein
p24 as previously described [17]. Viral preparations underwent a
single freeze-thaw cycle before use. MDMs (5610
5/well in 6-well
plates, 5610
4/well in 24-well plates) were infected with NL4-3-
Bal-IRES-HSA virus (10 ng of p24/10
5 cells) for 2 hours, washed
extensively with media to remove unadsorbed virions, and
cultured for 6 days (unless otherwise indicated) before contact
with L. infantum amastigotes or zymosan particles. In some
experiments, 6-day old virus-infected or uninfected MDM
supernatants were harvested, filtered through a 0.22 mm-pore size
cellulose acetate membrane (Millipore, Bedford, MA), treated with
Efavirenz (EFZ), a non-nucleoside HIV-1 reverse transcriptase
inhibitor (50 nM, from the Division of AIDS, NIAID, NIH,
through the NIH AIDS Repository Reagent Program, German-
town, MD) and stored at 280uC until use.
Cytokines, Tat protein, and binding assays for LRPAP/RAP
and annexin V phosphatidylserine
HIV-1 Tat protein (used at a final concentration of 100 ng/ml,
from Dr. John Brady and DAIDS, NIAID) and rabbit anti-Tat
antiserum (used at a dilution of 1:500, from Dr. Bryan Cullen) and
Maraviroc (MVC, used at 50 nM) were obtained through the NIH
AIDS Repository Reagent Program. Tat protein was reconstituted
in phosphate-buffered saline (PBS) containing 1 mg/ml bovine
serum albumin (BSA, Sigma) and 0.1 mM dithiothreitol (DTT). IL-
10 and TGF-b (both from Peprotec, Rocky Hill, NJ) were used at
concentrations of 10 ng/ml and 2 ng/ml, respectively. The mouse
anti-TGF-b neutralizing antibody MAB240 (R&D Systems,
Minneapolis, MN) was used at a final concentration of 10 mg/ml.
In some TGF-b inhibition assays, type I Furin inhibitor was used at
a final concentration of 50 mM (EMD Biosciences, San Diego, CA)
and X-VIVO 20 (Lonza BioWhittaker, Walkersville, MD) media
was used in some cases. To inhibit phosphatidylserine-mediated
phagocytosis, annexin V (BioVision, Mountain View, CA) was
added to Leishmania parasites or zymosan particles in annexin V-
binding buffer (100 mM HEPES, 150 mM NaCl, 5 mM KCl,
5 mM CaCl2 and 1 mM MgCl2 [pH 7.4]) to the indicated final
concentrations for 30 min, prior to phagocytosis. To inhibit CD91/
LRP-1-mediated phagocytosis, MDMs were treated with 2 mM
LRPAP/RAP (R&D Systems) prior and during phagocytosis of
Leishmania parasites, or control zymosan particles, for 4 hours.
Leishmania parasites, zymosan particles and
phagocytosis assays
Non-transfected or green fluorescent protein (GFP)-expressing
L. infantum axenic amastigotes transfected with pNEO-GFP (kindly
provided by Dr. B. Papadopoulou) [11], were maintained in
MAA/20 medium at 37uC in a 5% CO2 incubator. MAA/20
consists of modified 199 medium (Gibco/Invitrogen) with Hank’s
salts, supplemented with 0.5% soybean trypto-casein (Pasteur
Diagnostics, Marne la Coquette, France), 15 nM D-glucose,
5 mM L-glutamine, 4 mM NaHCO3, 0.023 mM bovine haemin,
25 mM HEPES (at a final pH of 6.5) and 20% fetal bovine serum.
Prior to phagocytosis assays, the concentration of Leishmania
parasites was determined using a hemocytometer, and parasites
were added to MDMs seeded on coverslides at a 5:1 ratio (10:1 in
the case of the annexin V phosphatidylserine-binding assay).
Alternately, Alexa488-labeled zymosan particles (Molecular
Probes/Invitrogen, Burlington, ON) were opsonized in RPMI-
1640 medium supplemented with 10% complement C5-depleted
human serum (C1163, Sigma, St-Louis, MO), and added to
MDMs (5 particles/cell, as previously determined by microscopy
analysis of serial dilutions of zymosan). After 1 hour, excess targets
(i.e. Leishmania parasites or zymosan) were washed out, and
macrophages were cultured for an additional 3 hours to ensure full
phagocytosis of targets. Cells were then fixed in 4% paraformal-
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rescence staining.
Immunofluorescence staining and microscopy
Following fixation in 4% paraformaldehyde, MDMs on
converslides were permeabilized with 0.1% (v/v) Triton X-100
(Sigma) and non-specific binding sites blocked with 1% (w/v) BSA,
10% (v/v) of a pool of decomplemented human sera from several
donors and 20% (v/v) normal goat serum (Jackson ImmunoR-
esearch/Cedarlane, West Grove, PA). In the case of HIV-1-
infected MDMs, cells were then stained with rat anti-HSA (1:300
dilution, clone M1/69, BD Biosciences, Mississauga, ON), washed
in PBS, and further stained with mouse anti-rat IgG conjugated to
Alexa555 (1:500, Molecular Probes/Invitrogen) and the DNA
probe DRAQ5 (1:1000, Biostatus, Leicestershire, UK). Alterna-
tively, MDMs were stained with Alexa555-conjugated phalloidin
(Molecular Probes/Invitrogen) and/or DRAQ5. Stained cells
were then mounted using Fluoromount G (Southern Biotech/
InterScience, Birmingham, AL) and sealed.
The amounts of internalized Leishmania parasites or zymosan
particles in MDMs were determined by confocal scanning
microscopy, using an Olympus FluoView FV300 microscope
(Olympus, Markham, ON) equipped with the appropriate lasers
and filters. Further digital imaging was performed using Adobe
Photoshop software (v. 6.0, Adobe Systems, San Jose, CA) and
NIH ImageJ 1.38, and careful image analysis was done to ensure
that all counted targets were fully internalized.
Flow cytometry analysis of CD91/LRP-1 surface
expression
MDMs were harvested by gentle scraping after incubating
10 min at 37uC in PBS containing 5 mM EDTA, washing and
fixing in 4% paraformaldehyde. Non-specific binding sites were
then blocked with 1% (w/v) BSA, 10% (v/v) of a pool of
decomplemented human sera from several donors and 20% (v/v)
normal goat serum. Surface expression of CD91/LRP-1 was
determined using FITC-labeled mouse anti-human CD91 anti-
bodies (1:100; BD Biosciences/Pharmingen). Controls consisted of
cells labeled with an isotype-matched FITC-tagged antibody
(IgG1k). Cells were analyzed using a Coulter EPICS XL flow
cytometer (Beckman-Coulter, Miami, FL) and FCS express
software. A minor displacement of control curves were observed
in HIV-1-infected MDMs (as compared to uninfected cells), and
was taken into account.
Statistical analysis
The total number of GFP-tagged Leishmania parasites or
fluorescent-labeled zymosan particles per 100 MDMs (i.e. produc-
tively infected with HIV-1/HSA-positive, uninfected bystander/
HSA-negative and mock-infected control) were determined. Results
presented are expressed as means 6 standard error of the mean
(SEM) of triplicate samples. Results shown are of experiments from
cells derived from one donorrepresentative of at least three different
healthy blood donors. Analyses were performed using Student’s
two-sample one (when mentioned) or two-tail unequal variance
tests. P values of ,0.05 were deemed statistically significant.
Results
HIV-1 infection augments internalization and survival of
Leishmania parasites in uninfected bystander MDMs
It has been established that HIV-1 infection markedly enhances
Leishmania proliferation in MDMs [11,14]. However, it is still
unclear whether the HIV-1-mediated enhancement of parasite
growth occurs in MDMs productively infected with HIV-1 and/or
uninfected bystanders cells (i.e. uninfected cells residing in a
population also containing virus-infected cells). It was therefore of
high interest to investigate and compare the entry and survival of
Leishmania parasites in both uninfected bystander and HIV-1-
producing macrophage subpopulations. To this end, we used a
fully competent R5-tropic, HSA-encoding viral construct to
discriminate between both populations, by the expression of the
HSA reporter cell surface molecule. Moreover, studies were all
performed with L. infantum amastigotes because it is the Leishmania
strain most frequently diagnosed in co-infected individuals and the
amastigote form is considered as the developmental stage of the
parasite that is responsible for maintaining and spreading the
parasitic infection in humans.
Following 6 days of HIV-1 infection, we observed, using
fluorescence confocal microscopy, that between 7 and 12% of
MDMs (compiled from 9 independent donors) were productively
infected with HIV-1 (i.e. HSA+) (data not shown). We then
compared the capability of productively-infected and uninfected
bystander MDMs, along with mock-infected control cells, to
internalize GFP-expressing Leishmania parasites. We also assessed
the phagocytic index of zymosan using complement-opsonized
Alexa488-labeled particles based on the notion that such protein-
carbohydrate complexes prepared from yeast cell wall are
commonly used targets in phagocytosis assays. Representative
confocal microscopy images of mock-infected (i.e. without HIV-1)
(left panels) or MDMs inoculated with HIV-1 (i.e. both uninfected
bystander/HSA- and productively-infected cells/HSA+) (right
panels) are shown in Figure 1. As expected, quantitative analyses
of confocal microscopy images indicated that mock-infected
control cells internalized much higher amounts of zymosan
particles than uninfected bystander (i.e. HSA2) (P=0.006) and
HIV-1-infected MDMs (i.e. HSA+) (P=0.017) (Figure 2). More-
over, zymosan internalization was more efficient in uninfected
bystander cells compared to HIV-1-infected MDMs. On the other
hand, uninfected bystander MDMs exhibited a significant increase
in Leishmania phagocytosis, as compared to either their HSA-
expressing counterparts (P=0.008) or the mock-infected control
MDMs (P=0.049). Therefore, opposite effects were observed in
uninfected bystander MDMs compared to mock-infected control
MDMs concerning the engulfment of opsonized zymosan particles
(i.e. decrease) or the phagocytosis of Leishmania parasites (i.e.
increase).
MDMs productively infected with HIV-1 secrete a soluble
factor that enhances Leishmania uptake in uninfected
bystander cells
In order to identify by what mechanism Leishmania phagocytosis
was specifically enhanced in the uninfected bystander cell
subpopulation compared to HIV-1-infected MDMs, we investi-
gated if this effect was dependent on a soluble factor released by
productively HIV-1-infected MDMs. We therefore treated a fresh
culture of MDMs (i.e. uninfected with HIV-1) with 6-day old cell-
free supernatants from virus-infected or uninfected MDMs to
which was added Efavirenz (EFZ), a specific inhibitor of the virus-
encoded reverse transcriptase enzyme. This enabled us to abrogate
viral infection when such supernatants were added to new cultures
of MDMs, as detected by ELISA against the major core p24
protein for up to 7 days (data not shown). As depicted in Figure 3,
a 24-hour exposure of uninfected MDMs to supernatants from
HIV-1-infected macrophages containing EFZ was sufficient to
enhance Leishmania phagocytosis to more than 50% of those found
in untreated control MDMs, but to similar levels found in cells
HIV-1/Leishmania Macrophage Co-Infections
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multiplication and survival [18]. Additionally, a significant drop in
the ability of the supernatant-treated cells to internalize zymosan
particles was also observed as compared to untreated cells
(P=0.029). These results suggested that a soluble factor present
in cell-free supernatants from HIV-1-infected MDMs was
responsible for the higher parasite uptake in uninfected bystander
cells.
Tat and TGF-b secretion enhance parasite entry in MDMs
It has previously been reported that the addition of the HIV-1
early protein Tat to MDM supernatants leads to enhanced
internalization of L. amazonensis promastigotes [14]. In order to
investigate which soluble factor(s) is responsible for the enhanced
uptake of L. infantum amastigotes in uninfected bystander cells, we
added Tat or TGF-b to the supernatants of MDMs for 24 hours
prior to addition of fluorescent-tagged parasites or zymosan
particles. The use of TGF-b is supported by the previous
demonstration that this cytokine is induced by Tat [19] and can
increase the survival of intracellular parasites in macrophages [15].
As illustrated in Figure 4, a significant increase in Leishmania
internalization within MDMs was observed when either Tat
(P=0.0067) or TGF-b (P=0.016) was added, as compared to
untreated control cells or cells treated with uninfected MDM
Figure 1. HIV-1 infection exerts a different effect on MDM phagocytosis of zymosan particles or Leishmania parasites. Mock-infected
control MDMs (panels A and C) or cells infected for 6 days with NL4-3-Bal-IRES-HSA reporter virus (panels B and D) were put in contact either with
complement-opsonized Alexa488-tagged zymosan particles (panels A and B) or GFP-expressing Leishmania parasites (panels C and D) (both shown in
green) for 1 hour. Next, excess zymosan particles/Leishmania amastigotes were washed out and MDMs cultured for an additional 3 hours. Cells were
then fixed, mounted and immunostained for HSA (shown in red) and DNA (using DRAQ5, shown in blue) to detect HIV-1-infected cells and Leishmania
DNA/host cell DNA, respectively. Shown are representative images obtained by confocal microscopy. Arrows indicate uninfected bystander MDMs
displaying numerous internalized Leishmania parasites.
doi:10.1371/journal.pone.0032761.g001
Figure 2. Leishmania parasites are internalized more efficiently
in uninfected bystander MDMs compared to virus-infected
cells. The total numbers of complement-opsonized Alexa488-labeled
zymosan particles or GFP-expressing Leishmania parasites internalized
were determined in mock-infected control, uninfected bystander, or
productively HIV-1-infected MDMs, by fluorescence microscopy, as
previously illustrated in Figure 1. Results shown are of a single
representative donor out of a grand total of nine donors (mean number
of targets 6 SEM).
doi:10.1371/journal.pone.0032761.g002
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antibodies to Tat or TGF-b were added simultaneously with the
corresponding proteins. Furthermore, anti-Tat also inhibited the
up-regulatory effect of EFZ-treated supernatants from HIV-1-
infected macrophages on the amastigote uptake. These effects
were particularly significant with cells that internalized the higher
number of parasites (i.e. 5 or more) (data not shown).
Internalization of zymosan particles was reduced upon a treatment
with either Tat or TGF-b.
Tat affects phosphatidylserine-mediated phagocytosis
We next investigated how the addition of Tat exerts a positive
effect on Leishmania parasite entry, whereas it can significantly
reduce the intake of zymosan particles. Although HIV-1 infection
is generally considered to inhibit phagocytosis [6–9], it is possible
that uptake is enhanced in specific cases involving Tat or TGF-b.
Since Leishmania amastigotes use phosphatidylserine-mediated
phagocytosis to enter phagocytes [20–22], we set out to determine
if this mechanism is promoted in Tat-treated MDMs. In order to
answer this fundamental question, the phosphatidylserine-binding
protein annexin V was used to mask this residue at the surface of
Leishmania amastigotes. The binding of annexin V was specific to
amastigotes since this molecule displays no effect with respect to
the uptake of complement-opsonized zymosan particles in MDMs
(Figure 5). However, as little as 2 mg/ml of annexin V was
sufficient to inhibit the Tat-dependent increase in Leishmania entry
(P,0.0001). Further increasing concentrations of annexin V
brought amastigote phagocytosis to levels below that of control
macrophages (i.e. untreated with Tat), although at a slower rate of
inhibition.
HIV-1-mediated enhanced amastigote intake is linked to
increased levels of CD91/LRP-1
If phosphatidylserine-mediated phagocytosis of Leishmania is
increased by Tat or TGF-b, then such enhanced entry may be due
to greater surface expression of phosphatidylserine-binding
receptors on MDMs. We therefore analyzed the surface expression
of putative phosphatidylserine receptors such as scavenger
receptor CD36 [23], phosphatidylserine receptor (PSR) [24], or
brain-specific angiogenesis inhibitor 1 (BAI-1) [25] on virus-
infected macrophage populations, or on MDMs treated with
TGF-b, Tat, or supernatants from HIV-1-infected cells. We did
not find any statistically significant differences in the three studied
phosphatidylserine-binding receptors for the untreated or treated
MDMs (data not shown).
Given that the cell surface expression of the three tested
receptors that directly interact with phosphatidylserines is not
enhanced by Tat or TGF-b, we investigated if receptors involved
indirectly with phosphatidylserine-mediated phagocytosis, such as
CD91/LRP-1, were upregulated in such conditions. As shown in
Figure 6, MDMs either exposed to Tat or TGF-b for a brief time
period (i.e. 24 hours) showed a slight but reproducible enhance-
ment of surface expression of CD91/LRP-1 when compared to
untreated control cells (called mock). However, as illustrated in
Figure 7, the increase in surface CD91/LRP-1 was much greater
in 6 day old HIV-1-infected MDMs.
In order to directly demonstrate the contribution of CD91/
LRP-1-mediated phagocytosis in the HIV-1-dependent enhance-
ment in Leishmania parasite uptake by uninfected bystander
MDMs, we analyzed the effect of LRPAP/RAP, an antagonist
of CD91/LRP-1-ligand interactions [26], on Leishmania or
zymosan phagocytosis in HIV-1-infected MDM populations.
Mock- or HIV-1-exposed macrophages were therefore treated
with LRPAP/RAP prior and during phagocytosis of Leishmania
parasites or zymosan particles. As shown in Figure 8A, a
significant decrease in Leishmania parasite internalization was
observed in uninfected bystander MDMs in presence of LRPAP/
RAP when compared to the untreated counterpart (one tail,
P=0.038). Indeed, addition of the agonist brought down the
numbers of internalized parasites in uninfected bystander cells to
levels found in uninfected MDMs (P=0.58). As shown in
Figure 8B, the addition of LRPAP/RAP had no effect on
zymosan phagocytosis, and thus was specific to CD91/LRP-1-
mediated phagocytosis (P=0.12).
HIV-1 infection activates TGF-b, which in turn
upregulates surface expression of CD91/LRP-1
Given our previous observations that Tat (and TGF-b) augment
surface CD91/LRP-1 on macrophages, on one hand, and that
HIV-1 infection enhances Leishmania internalization in uninfected
bystander MDMs, on the other, we set out to determine if virus
infection promotes either TGF-b secretion or activation. Quan-
titative analysis of newly synthesized TGF-b transcripts in HIV-1-
infected MDM populations, as compared to uninfected cells,
determined that no significative change in TGF-b transcription
was induced by HIV-1 (data not shown). However, given that
much TGF-b is secreted in an inactive form [27,28], and that
serum is a rich source of TGF-b [27], we investigated if HIV-1
Figure 3. MDMs productively infected with HIV-1 secrete a
factor that is necessary for inducing enhanced Leishmania
parasite intake. MDMs were treated for 24 hours with cell-free
supernatants from 6-day old virus-infected macrophages or uninfected
MDM supernatants supplemented with EFZ. Mock-treated cells or
MDMs treated for 24 hours with IL-10 were used as controls. Next,
MDMs were pulsed for 1 hour either with complement-opsonized
Alexa488-labeled zymosan particles or GFP-expressing Leishmania
parasites. Thereafter, excess zymosan particles/Leishmania parasites
were washed out and MDMs cultured for another 3 hours. After fixing
and mounting the cells, the numbers of internalized zymosan particles
or Leishmania parasites were then determined by fluorescence
microscopy. Results are from a donor representative of three (mean
number of targets 6 SEM).
doi:10.1371/journal.pone.0032761.g003
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containing media. This was achieved by comparing the TGF-b-
dependent rise of surface CD91/LRP-1 in 8-hour HIV-1-infected
macrophages in the presence of Furin inhibitor I, which has been
reported to suppress TGF-b activation [29–31]. As shown in
Figure 9A, MDMs treated prior and during HIV-1 infection with
the viral entry inhibitor Maraviroc (MVC), a CCR5 antagonist, or
EFZ had similar levels of surface CD91/LRP-1 as compared to
uninfected MDMs. This indicates that productive HIV-1 infection
is required to modulate surface expression of the scavenger
receptor CD91/LRP-1 in MDMs. Interestingly, MDMs treated
with either Furin inhibitor I, or neutralizing anti-TGF-b
antibodies, at the time and following HIV-1 infection expressed
significantly less surface CD91/LRP-1 as compared to untreated
cells (Figure 9B). These data suggest that productive HIV-1
infection triggers the release of TGF-b activation factor(s) which,
in turn, enhances CD91/LRP-1 surface expression in MDMs.
Discussion
The growing spread of the HIV-1 pandemic from urban centers
to outlying periurban and rural areas in developing countries has
given rise to new opportunistic co-infections. Although many of
the first Leishmania/HIV-1 co-infections were observed in Southern
Europe and the Mediterranean basin [1], and were strongly
prevalent among intravenous drug users, Leishmania has taken
advantage of the growing HIV-1 geographical overlap and is now
considered as a significant opportunistic infection [1,2]. In
addition, both Leishmania and HIV-1 act to each other’s benefit
in the co-infected individual. Indeed, HIV-1 often reinitiates or
worsens Leishmania infections, whereas the presence of the
Figure 4. Tat and TGF-b mediate enhanced Leishmania parasite intake in MDMs. Cells were either left untreated, or treated for 24 hours
with uninfected MDM supernatants, Tat or TGF-b, prior to a 1 hour exposure to Alexa488-labeled zymosan particles or GFP-expressing Leishmania
parasites. In some cases, anti-Tat, or anti-TGF-b neutralizing antibodies, were added at the time of incubation with either Tat or TGF-b, respectively.
Alternatively, anti-Tat was added to supernatants from HIV-1-infected macrophages, and this mix added to MDMs at 24 hours before performing the
phagocytosis assay. Thereafter, excess zymosan particles/Leishmania parasites were washed out and MDMs cultured for another 3 hours. Numbers of
internalized zymosan particles or Leishmania parasites were determined as described in Materials and Methods. Results are the means obtained from
a donor representative of three (mean number of targets 6 SEM).
doi:10.1371/journal.pone.0032761.g004
Figure 5. Enhanced intake of Leishmania parasites in uninfected
bystander MDMs is dependent on a surface macrophage
receptor for phosphatidylserine. Alexa488-labeled zymosan parti-
cles or GFP-expressing Leishmania parasites were first pre-incubated for
30 min in annexin V-binding buffer with the listed concentrations of
annexin V, and added to MDMs previously treated or not with Tat. The
amount of internalized zymosan particles or Leishmania parasites was
determined asdescribedinMaterials andMethods. Resultsarethe means
of a donor representative of three (mean number of targets 6 SEM).
doi:10.1371/journal.pone.0032761.g005
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[1,2].
Both Leishmania and HIV-1 infect cells of the macrophage/
monocyte lineage. Furthermore, in co-infected cultures, the two
pathogens enhance their counterpart’s multiplication by inducing
an array of cytokines. For instance, in human primary dendritic
cell/CD4
+ T cell cocultures, L. infantum amastigotes enhance HIV-
1 production by inducing IL-6 and TNF-a [32]. Using human
Figure 6. Tat and TGF-b enhance CD91/LRP-1 surface expression in macrophages. MDMs were treated for 24 hours with either Tat (panel
A) or TGF-b (panel B), and cell surface CD91/LRP-1 determined by flow cytometry as described in Materials and Methods. Graphs shown are from
results obtained from a donor (depicted with an asterisk) chosen from the three reported in the small table below each graph. Different donors were
used in panels A and B. The percentage of CD91 positive cells and mean fluorescence intensity (MFI) (shown in parentheses) are illustrated for the six
different donors tested.
doi:10.1371/journal.pone.0032761.g006
Figure 7. HIV-1 infection enhances CD91/LRP-1 expression in macrophages. MDMs were infected for 6 days with HIV-1, and cell surface
expression of CD91/LRP-1 was determined by flow cytometry as described in Materials and Methods. The graphs shown is from results obtained from
a donor (depicted with an asterisk) chosen from the three reported in the small table below the graph. The percentage of CD91 positive cells and
mean fluorescence intensity (MFI) (shown in parentheses) are illustrated for the three different donors tested.
doi:10.1371/journal.pone.0032761.g007
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enhances HIV-1 replication in this cell type by the release of
the proinflammatory cytokines IL-1a and TNF-a [13]. On the
other hand, HIV-1 infection promotes Leishmania survival and
uptake by macrophages [11,14]. The fact that HIV-1 enhances
the parasite’s uptake sharply contrasts with most observations
concerning HIV-1’s effect on phagocytosis [6,7,8,9]. Indeed,
although HIV-1 infection has been reported to enhance entry of
other trypanosomatids, such as Blastocrithidia culicis [15], HIV-1
infection has been generally reported to inhibit macrophage
functions, including important signal transduction pathways and
mechanisms involved in phagocytic uptake of microbes and other
targets [7,9]. In this report, we further investigated the
mechanisms that allow for enhanced Leishmania uptake in HIV-
1-infected macrophages.
Our use of a novel HIV-1 construct encoding for all viral
proteins and murine HSA (CD24) allowed for efficient identifica-
tion of cells productively infected with HIV-1 and the surrounding
uninfected bystander cell counterpart. Quantitation of parasite
phagocytosis in both subpopulations clearly revealed that
uninfected bystander cells greatly account for the HIV-1-
dependent enhanced intake of L. infantum amastigotes in MDMs.
Our observations also suggest that cells productively infected with
HIV-1 release soluble factors which, in turn, act on uninfected
bystander neighbor cells. Although such factors are potentially
involved in higher parasite uptake, they could also account for the
loss in phagocytosis of complement-opsonized zymosan particles.
This two-way effect on phagocytosis was also observed in MDMs
treated with supernatants harvested from HIV-1-infected macro-
phages, in which virus replication was inactivated by the antiviral
Figure 8. HIV-1-mediated increase in Leishmania phagocytosis in uninfected bystander MDMs is inhibited by LRPAP/RAP. Mock-
infected or 6 day HIV-1-infected MDMs were treated for 4 hours with the CD91/LRP-1-ligand antagonist, LRPAP/RAP, prior and during phagocytosis of
Leishmania parasites (panel A) or zymosan particles (panel B), for 4 hours. MDMs were then fixed, stained and mounted for confocal microscopy
analysis as described in Materials and Methods. The numbers of internalized targets were then determined. Results shown are the means of four
distinct donors 6 SEM.
doi:10.1371/journal.pone.0032761.g008
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soluble, secreted compounds from HIV-1-infected macrophages
are directly responsible for the superior uptake of Leishmania
parasites by uninfected bystander MDMs.
Barreto-de-Souza and colleagues found that enhanced multi-
plication of L. amazonensis in HIV-1-infected MDM cultures is
driven primarily by the release of the viral Tat protein, which in
turn induces cyclooxygenase-2 (COX-2) expression [14]. Further-
more, it was also found that neutralization of TGF-b1 reduced the
Tat-mediated effect on parasite growth. Tat is a small protein that
interacts with the transactivation response element at the 59-end of
viral mRNAs. In addition to this, Tat is released by infected cells,
as has been reported in in vitro and in vivo studies [33,34]. Thus, the
viral protein can be internalized by surrounding neighbor cells,
affecting their normal function, inducing apoptosis, or modulating
cytokine secretion. Of particular interest, both IL-10 and TGF-b1
induction in macrophages have been associated with the presence
of Tat [19,35]. We found that the addition of either Tat, IL-10, or
TGF-b to MDMs is sufficient to both enhance L. infantum
amastigote entry into macrophages and, on the other hand,
inhibit complement-opsonized zymosan phagocytosis. According-
ly, IL-10 and TGF-b have been reported to decrease phagocytic
function in macrophages [36], and HIV-1 infection has been
reported to inhibit complement receptor-mediated entry [6].
Interestingly, Barreto-de-Souza and co-workers used promasti-
gotes as targets throughout their experiments [14], therefore
suggesting that Tat also enhances promastigote survival and
differentiation into amastigotes, in addition to parasite entry into
macrophages. Using L. infantum promastigotes, we also observed
elevated entry into virus-infected MDMs populations, and, as with
amastigotes, found that uninfected bystander cells had internalized
most of the parasites (data not shown). However, given that entry
pathways used by promastigotes and amastigotes in macrophages
can be significantly different, further studies are needed to address
which receptors are involved in the Tat-mediated enhanced
uptake of promastigotes in MDMs. Interestingly, it is also possible
that at least some promastigotes use phosphatidylserine as a mode
of entry into macrophages, as recently reported [37,38].
Several reports have suggested that Leishmania amastigotes,
among other parasites, enter phagocytes using phosphatidylserine
residues exposed on the parasite surface [22,39]. This ensures
minimal monocyte/macrophage activation, and mimics the intake
of apoptotic cells. Furthermore, it has been previously reported
that both TGF-b and IL-10 are produced in such anti-
inflammatory situations [22,40]. In addition to these observations,
HIV-1 replication is upregulated by the phagocytosis of apoptotic
cells [41,42], therefore suggesting that the resulting anti-inflam-
matory cytokines may also contribute to viral pathogenesis.
Accordingly, we were successful in inhibiting Leishmania amastigote
entry in MDMs using annexin V. The annexin-V-mediated effect
was specific to amastigotes, since complement-opsonized zymosan
phagocytosis was not affected. In Tat-treated MDMs, annexin V
sharply reversed any Tat-mediated enhanced Leishmania internal-
ization, suggesting that Tat’s effect on Leishmania entry is greatly
dependent on the parasite’s surface phosphatidylserines. However,
the annexin V-mediated decrease in amastigote entry was less
efficient at higher concentrations, possibly indicating that other
modes of entry are also used once a saturating amount of annexin
V has blocked all available phosphatidylserine.
Several macrophage receptors have been implicated in the
phagocytic process of apoptotic cells [43]. However, not all the
receptors that bind phosphatidylserine have been fully character-
ized. For instance, a putative receptor named PSR [24], was at
first a strong candidate, though it is now clearly dissociated with
phosphatidylserine-mediated phagocytosis [43]. The scavenger
receptor CD36 [23], and more recently BAI-1 [25], TIM-4
[44,45] and Stabilin-2 [46] have all been proposed to bind
phosphatidylserine residues. However, CD36 and TIM-4 may
only be involved in binding or tethering, and not full target
engulfment [47]. Given that none of the surface expression of
these receptors were upregulated by HIV-1 infection in MDMs,
we focused on receptors of phosphatidylserine-binding ligands,
such as CD91/LRP-1. CD91/LRP-1 binds b2-glycoprotein,
which has been reported to interact with phosphatidylserines of
apoptotic bodies [26]. Our findings that surface CD91/LRP-1 is
increased in MDMs treated with Tat, as well as following HIV-1
Figure 9. HIV-1 infection of MDMs activates serum TGF-b, leading to enhanced cell surface CD91/LRP-1 expression. HIV-1-infected
MDMs were treated either with MVC or EFZ (panel A) or either neutralizing TGF-b antibodies or Furin inhibitor I (panel B) during HIV-1 infection for
8 hours, and cell surface CD91/LRP-1 determined by flow cytometry as described in Materials and Methods. Both uninfected and untreated HIV-1-
infected MDMs were used as controls. Graphs shown are from results obtained from a donor (shown with an asterisk) chosen from the three reported
in the small table below each graph. Different donors were used in panels A and B. The percentage of CD91 positive cells and mean fluorescence
intensity (MFI) (shown in parentheses) are illustrated for the six different donors tested.
doi:10.1371/journal.pone.0032761.g009
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enhanced amastigote uptake by macrophages. This hypothesis was
confirmed by the use of the CD91/LRP-1-ligand interaction
antagonist LRPAP/RAP, which inhibited the enhanced Leishmania
entry in HIV-1-infected macrophage populations. Thus, amasti-
gote/b2-glycoprotein complexes are taken in more efficiently in
HIV-1-infected MDM populations, having greater access to the
CD91/LRP-1 receptor. Even though uninfected bystander
MDMs in HIV-1 infection account for Leishmania enhanced entry
(not the macrophages productively infected with HIV-1), it is
possible that both macrophage subpopulations may express higher
levels of surface CD91/LRP-1. It is possible that productively
HIV-1-infected MDMs are unable to sustain additional Leishmania
entry/multiplication, given their underlying viral infection.
Finally, it is noteworthy that not all phosphatidylserine-mediated
phagocytosis is necessarily enhanced by HIV-1 infection, since
apoptotic cell phagocytosis may also be inhibited by the virus in
certain cases [9].
Although we found that neutralizing anti-TGF-b antibodies
were sufficient to counteract the effect of either HIV-1 infection or
that of the addition of TGF-b on CD91/LRP-1 surface expression
and Leishmania entry in MDMs, respectively, it is noteworthy that
we were unable to detect, by quantitative RT-PCR, production of
newly secreted TGF-b in HIV-1-infected MDM populations.
Furthermore, enhanced surface CD91/LRP-1 expression could be
detected as early as 8 hours following HIV-1 infection, suggesting
that the mechanisms involved were happening early in the virus
infection process. Indeed, since Efavirenz efficiently inhibited
enhanced amastigote entry, some early active steps in the HIV-1
viral cycle must be linked to extracellular TGF-b activation and
CD91/LRP-1 surface expression. Our Furin inhibitor I assays also
suggest the existence of such mechanisms. It is therefore
conceivable that some host factor(s), in reaction to HIV-1
infection, or even HIV-1 viral factors may lead to TGF-b
activation. In this regard, Tat produced prior to HIV-1 integration
has been reported in infected cells [48]. However, further
investigation into these mechanisms is needed.
In the last few years, a concept derived by analogy to the CD4
+
T helper cell paradigm (i.e. Th1, Th2 and Th17 effector cells) has
been developed based on a polarization of macrophages into
opposing pro- and anti-inflammatory programs [36,49,50]. In this
model, M1 macrophages produce IL-1b and TNF-a, reactive
oxygen and nitrogen intermediates, among others, whereas M2
macrophages, which display a higher heterogeneity, secrete IL-10
and express scavenger and mannose receptors. Among M2 cells,
the M2c subpopulation is induced primarily by IL-10 and has a
role in immune response suppression [36,50]. Given our current
observations on IL-10 and TGF-b, and their impact on
Leishmania/HIV-1 interactions in macrophages, further investiga-
tion into M2c macrophage polarization and possible modulation
by HIV-1 Tat may help in the understanding of the complex
interactions between these two important human pathogens.
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